Private Equity Fund Investments
CRO firm Veeda Clinical Research raises $16-M led by Sabre PE
Ahmedabad-based IPO-bound Veeda Clinical Research has raised USD 16 million (around INR 118 crore) in a funding round led by Sabre Partners through its fourth fund. The growth capital round also saw participation from high networth individuals such as Pranab Mody of JB Chemicals, Havells India family office, Nikhil Vora of Sixth Sense Ventures, and Arjun Bhartia of Jubilant. Veeda offers a range of bioequivalence studies and clinical trials to generic and innovator pharmaceutical companies.
From the Venture Intelligence PE-VC Deal Database: In November 2018, CX Partners Fund had acquired a majority stake in Veeda Clinical Research.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
